Noxon

Executive Summary

Noxon is a Berlin-based biotech company pioneering RNA therapeutics for rare genetic diseases. Founded in 2020, the company leverages antisense oligonucleotides (ASOs) and other RNA-targeting modalities to correct disease-causing genetic defects in severe monogenic disorders lacking approved treatments. With a focus on precision medicine, Noxon's pipeline targets conditions with high unmet need, aiming to provide life-changing therapies for patients. The company has built a proprietary platform for rapid ASO design and screening, enabling efficient development across multiple targets. Currently in Phase 1 clinical stage, Noxon has raised sufficient funding to advance its lead candidate through initial proof-of-concept studies. The company's approach aligns with the growing trend of personalized genetic medicines, and its geographic location in Germany provides access to top talent and EU regulatory pathways. With a lean team of 50-200 employees, Noxon combines scientific rigor with operational agility.

Upcoming Catalysts (preview)

• Q2 2027Phase 1/2 interim data readout for lead ASO candidate60% success
• Q4 2026IND filing for second ASO program75% success
• TBDStrategic partnership or licensing deal for platform technology40% success